NCT06851065View on ClinicalTrials.gov

A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

Active, not recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Luspatercept

As per product lable

DRUG

Erythropoiesis-stimulating agents

As per product label

Trial Locations (1)

27709-2194

RTI Health Solutions, Raleigh

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06851065 - A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States | Biotech Hunter | Biotech Hunter